Clinical Trials Logo

Clinical Trial Summary

The primary objective is to describe the safety and tolerability of ticagrelor, by assessment of adverse events (characteristics, reporting rate, severity, relationship and risk factors), especially the bleeding events as defined in 8.1 and other serious adverse events (SAEs) during 1-year follow up in Chinese acute coronary syndrome (ACS) patients.


Clinical Trial Description

The trial is a multi-centre, prospective cohort, non-interventional study to be conducted in the department of cardiology from approximately 20 tier-2 or 3 hospitals, China. The study requires Chinese subjects aged over 18, diagnosed as ACS and treated with ticagrelor at least one tablet from the department of cardiology in the around 20 tier-2 or 3 hospitals. The subjects will be tracked up to 1 month after the discontinuation of ticagrelor for AE events and 1 year after enrollment for major cardiovascular events. This is an observational study. The prescribing doctor is in charge of prescribing or discontinuation ticagrelor. The investigator in an observational study may not intervene in the treatment. All 1000 subjects' related data will be collected ;


Study Design


Related Conditions & MeSH terms


NCT number NCT02430493
Study type Observational [Patient Registry]
Source AstraZeneca
Contact
Status Completed
Phase N/A
Start date May 28, 2015
Completion date March 29, 2017

See also
  Status Clinical Trial Phase
Terminated NCT00385138 - Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition. Phase 3
Completed NCT01944800 - Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome Phase 4
Completed NCT02286544 - Effects of Oxygen Treatment on Mechanisms Involved in Ischemia-reperfusion Injury: A Pilot Study in Healthy Volunteers Phase 1
Completed NCT02290080 - Determination of the Role of Oxygen in Suspected Acute Myocardial Infarction by Biomarkers Phase 3
Completed NCT01405287 - Study of Vascular Healing With the Combo Stent Versus the Everolimus Eluting Stent in ACS Patients by Means of OCT Phase 2
Completed NCT00767507 - Maintenance of Platelet Inhibition With Cangrelor Phase 2
Completed NCT03672097 - Prasugrel Switching Study in Patients With Acute Coronary Syndrome (ACS) Who Underwent Percutaneous Coronary Intervention (PCI) Phase 4
Completed NCT00399880 - Improving Medication Adherence Through Graphically Enhanced Interventions in Acute Coronary Syndromes N/A
Completed NCT01994577 - Optimum Troponin Cutoffs for ACS in the ED
Completed NCT00313300 - Safety Study of Apixaban in Recent Acute Coronary Syndrome Phase 2
Completed NCT02244710 - EndoTic - Endothelium and Ticagrelor N/A
Active, not recruiting NCT04090281 - Implementing Precision Medicine Approaches to Guide Anti-platelet Selection Phase 4
Active, not recruiting NCT03581578 - VITROS Immunodiagnostic Products hs Troponin I
Recruiting NCT04116931 - OPTImal Management of Antithrombotic Agents: OPTIMA-5 Phase 4
Completed NCT02171065 - PROSPECT II & PROSPECT ABSORB - an Integrated Natural History Study and Randomized Trial. N/A
Completed NCT00855257 - Assessment of Endothelial Vasomotricity After Treatment by Nicotinic Acid in Acute Coronary Syndrome Phase 3
Completed NCT02733341 - The Effect of IV Cangrelor and Oral Ticagrelor Study Phase 4
Completed NCT02184884 - Effect of Perioperative Clopidogrel Responsiveness on Ischemic Outcome in Patients With Acute Coronary Syndrome Undergoing Off-pump Coronary Artery Bypass Surgery
Completed NCT00932100 - A Study Assessing the REG1 Anticoagulation System Compared Heparin in Subjects With Acute Coronary Syndrome Phase 2
Recruiting NCT02018497 - Essential Hypotension and Allostasis Registry